

University of Groningen

## Cardiovascular effects of non-cardiovascular drugs in heart failure

Yurista, Salva

DOI:  
[10.33612/diss.132706675](https://doi.org/10.33612/diss.132706675)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2020

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*  
Yurista, S. (2020). *Cardiovascular effects of non-cardiovascular drugs in heart failure*. University of Groningen. <https://doi.org/10.33612/diss.132706675>

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Stellingen behorende bij het proefschrift:

**Cardiovascular effects of non-cardiovascular drugs in heart failure**

Salva R. Yurista

1. SGLT2 inhibition with empagliflozin improves cardiac function and ameliorates cardiac remodelling in experimental models of heart failure without diabetes. *This thesis and J Am Coll Cardiol. 2019 Apr 23;73(15):1931-1944*
2. The cardiovascular benefits of empagliflozin are accompanied by a marked increase in circulating ketone levels, increased cardiac ketone utilization, and partial normalization of myocardial energetics. *This thesis*
3. The beneficial effects of empagliflozin in non-diabetic HF are not offset by renal side effects, significant electrolyte imbalance or an increased fracture risk. *This thesis*
4. Factor Xa inhibition with apixaban does not influence pathological cardiac remodelling and cardiac function in rats with post-MI HF. These findings do not support the use of FXa inhibitors in HF patients without atrial fibrillation. *This thesis*
5. Chronic oral supplementation with ketone esters is effective in both prevention and treatment of heart failure in pre-clinical animal models. *This thesis*
6. Haastige spoed is zelden goed. *Dutch proverb*
7. Education isn't something you can finish. *Isaac Asimov*
8. Remember that sometimes not getting what you want is a wonderful stroke of luck. *Dalai Lama XIV*
9. COVID-19 has taught us to appreciate even the smallest things in life.